消化器内科 論文(2023年)
英語論文
| 著者 | タイトル | ジャーナル |
| Kawakami T, Todaka A, Oshima K, Fushiki K, Hamauchi S, Tsushima T, Yokota T, Onozawa Y, Yasui H, Yamazaki K. | Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin | BMC Cancer. |
| Tomoya Yokota, Hiroki Yukino, Mihoko Doi, Hisatsugu Ohori. | Real-World Experience of Tropomyosin Receptor Kinase Inhibition with Entrectinib in ETV6-NTRK3 positive Metastatic Salivary Secretory Carcinoma: A Case Series. | Head and Neck, in press |
| Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Hihara M, Soeda J, Misumi T, Yamamoto K, Akagi K, Ochiai A, Uetake H, Tsuchihara K, Yoshino T. | Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. | JAMA. |
| Nakai C, Mimaki S, Matsushima K, Shinozaki E, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Suzuki Y, Akagi K, Nomura S, Fujii S, Sugiyama M, Nishida N, Mizokami M, Koh Y, Koshizaka T, Okada H, Abe Y, Ohtsu A, Yoshino T, Tsuchihara K. | Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant. | Int J Clin Oncol. |
| Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J | Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. | Lancet. |
| Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, Shirasu H, Yamazaki K, Watanabe J, Kotaka M, Hirata K, Akazawa N, Kataoka K, Sharma S, Aushev VN, Aleshin A, Misumi T, Taniguchi H, Takemasa I, Kato T, Mori M, Yoshino T. | Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. | Nat Med. |
| Kawakami T, Yamazaki K. | The role of biomarker in later-line treatment for metastatic colorectal cancer | J Gastrointest Oncol |
| Matsubayashi H, Todaka A, Kawakami T, Hamauchi S, Yokota T, Higashigawa S, Kiyozumi Y, Harada R, Kado N, Nishimura S, Ishiwatari H, Sato J, Niiya F, Ono H, Sugiura T, Sasaki K, Yasui H, Yamazaki K. | Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients | J Hum Genet |
| Kataoka K, Yamada T, Taniguchi H, Ikeda M, Yamazaki K, Kanemitsu Y. | Corrigendum to “A ctDNA-driven multidisciplinary treatment strategy for resectable colorectal cancer -what surgical oncologists should know” [Eur. J. Surg. Oncol. 48(1) (2022) 1-2] | Eur J Surg Oncol |
| Yamamoto N, Koyama T, Shimizu T, Todaka A, Kawakami T, Erzen D, Sarashina A, Li B, Hou J, Yamazaki K. | Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors | Cancer Chemother Pharmacol |
| Yamazaki K, Yuki S, Oki E, Sano F, Makishima M, Aoki K, Hamano T, Yamamoto K. | Clinical outcomes of intensive versus less intensive first-line chemotherapy for metastatic colorectal cancer | Future Oncol |
| Taniguchi H, Yamazaki K, Masuishi T, Kawakami T, Onozawa Y, Honda K, Kadowaki S, Narita Y, Tsushima T, Hamauchi S, Todaka A, Yokota T, Ando M, Mori K, Shirasu H, Yasui H, Muro K. | Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study | Oncologist |
| Aoki Y, Nakamura Y, Denda T, Ohta T, Esaki T, Shiozawa M, Yamaguchi K, Yamazaki K, Sunakawa Y, Kato T, Okano N, Taniguchi H, Sato T, Oki E, Nishina T, Komatsu Y, Matsuhashi N, Goto M, Yasui H, Ohtsubo K, Moriwaki T, Takahashi N, Horita Y, Boku S, Wakabayashi M, Ikeno T, Mitani R, Yuasa M, Yoshino T. | Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy | JCO Precis Oncol |
| Matsubayashi H, Oishi T, Sasaki K, Abe M, Kiyozumi Y, Higashigawa S, Niiya F, Sato J, Ishiwatari H, Imai K, Hotta K, Kishida Y, Takada K, Ono H, Yamazaki K, Yasui H, Kenmotsu H, Kado N, Kagawa H, Shiomi A, Sugiura T, Bando E, Nishimura S, Hatakeyama K, Serizawa M, Harada R, Sugino T. | Discordance of microsatellite instability and mismatch repair immunochemistry occurs depending on the cancer type | Hum Pathol |
| Minamide T, Onozawa Y, Ono H. | A Unique Case of Giant Mushroom-like Gastric Tumor: Metastasis from Inferior Vena Cava Leiomyosarcoma | Gastrointest Endosc |
| Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, Ishii H, Mizusawa J, Katayama H, Kataoka T, Okusaka T, Ikeda M, Sasahira N, Miwa H, Mizukoshi E, Okano N, Mizuno N, Yamamoto T, Komatsu Y, Todaka A, Kamata K, Furukawa M, Fujimori N, Katanuma A, Takayama Y, Tsumura H, Fukuda H, Ueno M, Furuse J; Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group (JCOG). | A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407) | Eur J Cancer |
| Imaoka H, Ikeda M, Umemoto K, Sunakawa Y, Ueno M, Ueno H, Ozaka M, Kuwahara T, Okano N, Kanai M, Hisano T, Suzuki Y, Asagi A, Shioji K, Todaka A, Tsuji K, Ikezawa K, Miki I, Komatsu Y, Akutsu N, Yamashita T, Okuyama H, Furuse J, Nagano H. | Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment | Jpn J Clin Oncol |
| Ohgi K, Sugiura T, Okamura Y, Ashida R, Yamada M, Otsuka S, Todaka A, Uesaka K. | Long-term adjuvant chemotherapy after resection for pancreatic cancer patients with positive peritoneal lavage cytology | Langenbecks Arch Surg |
| Mizuno N, Ioka T, Ogawa G, Nakamura S, Hiraoka N, Ito Y, Katayama H, Takada R, Kobayashi S, Ikeda M, Miwa H, Okano N, Kuramochi H, Sekimoto M, Okusaka T, Ozaka M, Todaka A, Gotoh K, Tobimatsu K, Yamaguchi H, Nakagohri T, Kajiura S, Sudo K, Okamura K, Shimizu S, Shirakawa H, Kato N, Sano K, Iwai T, Fujimori N, Ueno M, Ishii H, Furuse J; Hepatobiliary and Pancreatic Oncology Group (HBPOG) of Japan Clinical Oncology Group (JCOG). | Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgroup analysis on systemic inflammatory response in JCOG1106 | Jpn J Clin Oncol |
| Watanabe M, Toh Y, Ishihara R, Kono K, Matsubara H, Miyazaki T, Morita M, Murakami K, Muro K, Numasaki H, Oyama T, Saeki H, Tanaka K, Tsushima T, Ueno M, Uno T, Yoshio T, Usune S, Takahashi A, Miyata H; Registration Committee for Esophageal Cancer of the Japan Esophageal Society. | Comprehensive registry of esophageal cancer in Japan, 2015 | Esophagus |
| Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, Kato K, Kato H, Kawakubo H, Kawachi H, Kuribayashi S, Kono K, Kojima T, Takeuchi H, Tsushima T, Toh Y, Nemoto K, Booka E, Makino T, Matsuda S, Matsubara H, Mano M, Minashi K, Miyazaki T, Muto M, Yamaji T, Yamatsuji T, Yoshida M. | Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1 | Esophagus |
| Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, Kato K, Kato H, Kawakubo H, Kawachi H, Kuribayashi S, Kono K, Kojima T, Takeuchi H, Tsushima T, Toh Y, Nemoto K, Booka E, Makino T, Matsuda S, Matsubara H, Mano M, Minashi K, Miyazaki T, Muto M, Yamaji T, Yamatsuji T, Yoshida M. | Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2 | Esophagus |
| Ura T, Hironaka S, Tsubosa Y, Mizusawa J, Kato K, Tsushima T, Fushiki K, Chin K, Tomori A, Okuno T, Matsushita H, Kojima T, Doki Y, Kusaba H, Fujitani K, Seki S, Kitagawa Y. | Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807 | Esophagus |
| Nonaka T, Kawashiro S, Ishikawa H, Ito Y, Nemoto K, Ishihara R, Oyama T, Oyama T, Kato K, Kato H, Kawakubo H, Kawachi H, Kuribayashi S, Kono K, Kojima T, Takeuchi H, Tsushima T, Toh Y, Booka E, Makino T, Matsuda S, Matsubara H, Mano M, Minashi K, Miyazaki T, Muto M, Yamaji T, Yamatsuji T, Yoshida M, Kitagawa Y; Esophageal Cancer Practice Guidelines Preparation Committee. | Concurrent chemoradiotherapy using proton beams can reduce cardiopulmonary morbidity in esophageal cancer patients: a systematic review | Esophagus |
| Kiyozumi Y, Goto K, Yoshikawa S, Kiyohara Y, Tsushima T, Kado N, Nishimura S, Higashigawa S, Harada R, Kunitomo K, Fukuzaki N, Matsubayashi H. | A Japanese case of familial malignant melanoma with germline CDK4 variant incidentally diagnosed by cancer genome profiling | J Hum Genet |
| Aoki M, Kadowaki S, Takahashi N, Suzuki T, Oshima K, Ando T, Yamamoto Y, Kawakami K, Kito Y, Matsumoto T, Shimozaki K, Miyazaki Y, Yamaguchi T, Nagase M, Tamura T, Amanuma Y, Esaki T, Miura Y, Akiyoshi K, Baba E, Makiyama A, Negoro Y, Nakashima K, Sugimoto N, Nagashima K, Shoji H, Boku N. | Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan | Gastric Cancer |
和文論文
| 著者 | タイトル | ジャーナル | |
| 安井博史、佐藤哲観、 | 静がんメソッド 緩和ケア編 | 日本医事新報社 | |
| 戸高 明子, 野呂瀬 朋子, 大池 信之 | 【膵癌・胆道癌2023(上)膵癌編-基礎・臨床の最新研究動向-】上皮性腫瘍 浸潤性膵管癌 特殊な組織型(臨床病理学的特徴) 退形成癌 | 日本臨床 | (0047-1852)81巻増刊2 膵癌・胆道癌2023(上)膵癌編 Page241-246 |
| 戸髙 明子 | 【肝胆膵がん治療の進歩2023】膵がん 切除不能例に対する殺細胞性抗悪性腫瘍薬 一次治療&二次治療 | 腫瘍内科 | (1881-6568)31巻2号 Page194-198 |
| 對馬 隆浩 | 進行再発食道癌に対する免疫チェックポイント阻害薬 | 医学と薬学 | 第80巻第4号 Pag367-373 |